Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0843
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer ; day:30 ; month:10 ; year:2018 ; pages:1-7
Cancer chemotherapy and pharmacology ; (30.10.2018), 1-7
- Creator
-
Fujii, Hironori
Yamada, Yunami
Watanabe, Daichi
Matsuhashi, Nobuhisa
Takahashi, Takao
Yoshida, Kazuhiro
Suzuki, Akio
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00280-018-3711-8
- URN
-
urn:nbn:de:101:1-2018121820395004900027
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Fujii, Hironori
- Yamada, Yunami
- Watanabe, Daichi
- Matsuhashi, Nobuhisa
- Takahashi, Takao
- Yoshida, Kazuhiro
- Suzuki, Akio
- SpringerLink (Online service)
Other Objects (12)
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer
UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer
Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9
Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study
A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC?
Global metabolic alterations in colorectal cancer cells during irinotecan-induced DNA replication stress
Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer
Polymorphisms within inflammatory genes and colorectal cancer
GSTT2 promoter polymorphisms and colorectal cancer risk
Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer
Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients
Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer
UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer
Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9
Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study
A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC?
Global metabolic alterations in colorectal cancer cells during irinotecan-induced DNA replication stress
Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer
Polymorphisms within inflammatory genes and colorectal cancer
GSTT2 promoter polymorphisms and colorectal cancer risk
Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer
Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients
Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer
UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer
Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9
Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study
A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC?
Global metabolic alterations in colorectal cancer cells during irinotecan-induced DNA replication stress
Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer
Polymorphisms within inflammatory genes and colorectal cancer
GSTT2 promoter polymorphisms and colorectal cancer risk
Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer
Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients